Investing.com - Financial Markets Worldwide
Get 40% Off
Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

BeyondSpring's lead candidate on par with Amgen's Neulasta in late-stage study; shares ahead 3%

Published 12/06/2018, 11:43 AM
Updated 12/06/2018, 11:43 AM
© Reuters. BeyondSpring's lead candidate on par with Amgen's Neulasta in late-stage study; shares ahead 3%
  • Ultra-thinly traded BeyondSpring (BYSI +3.2%) is up on almost double normal volume, albeit on turnover of only 12K shares, on the heels of its announcement of positive results evaluating lead candidate Plinabulin in patients receiving docetaxel chemotherapy.
  • The study met the primary endpoint of demonstrating the non-inferiority (no worse than) of Plinabulin compared to Amgen's (AMGN -1.7%) NEULASTA (pegfilgrastim) in reducing the duration of severe neutropenia (low levels of a type of white blood cell called neutrophils) in the first cycle of chemo.
  • The company plans to file a marketing applications in China and the U.S. seeking approval for Plinabulin for the treatment of chemo-induced neutropenia.
  • The company acquired global rights to Plinabulin, a small molecule synthetic analogue of a marine microbial product, from San Diego-based Nereus Pharmaceuticals in 2013.
  • Now read: Celgene (NASDAQ:CELG): Investment Thesis Still Not Compelling


Original article

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.